Skip to Main Content
Contribute Try STAT+ Today

Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember there are only a few more days until a holiday break arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Our choice today is cinnamon hazelnut (which may soon be in short supply, given the incredible shrinking Turkish economy). Meanwhile, here are some tidbits to help you along on your own journey. Speaking of which, we will hit the proverbial pause button to enjoy a respite. In other words, we will return on Jan. 3. Until then, we hope you have some time to enjoy yourselves. And of course, stay safe — wear a mask. See you next year, as they say …

The U.S. government expects to have about 4 million courses of Covid-19 treatments on hand by the end of January, including about 3 million courses of the Merck (MRK) pill and 250,000 of the Pfizer (PFE) pill, Bloomberg News reports. France, however, has cancelled its order for the Merck pill following disappointing trial data, becoming the first country to publicly acknowledge this step after the company released data in late November suggesting its drug was markedly less effective than previously thought, Reuters explains. France had placed an early order for 50,000 doses of the drug, known as molnupiravir.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment